Human Cytomegalovirus DNA among Women with Breast Cancer

Abstract

Breast cancer is the most common cause of death among women worldwide. Although there are many known risk<br />factors in breast cancer development, infectious diseases have appeared as one of the important key to contribute to<br />carcinogenesis formation. The effects of Human Cytomegalovirus (HCMV) on women with breast cancer has been<br />recently studied and reported. To contribute to this research trend, this study was conducted to evaluate the association<br />between HCMV and the women with breast cancer. Objective: This experiment aimed to evaluate HCMV DNA in women<br />with breast cancer in Ahvaz city, Iran. Materials and Methods: A total of 37 formalin fixed paraffin embedded tissues of<br />the patients with ductal breast carcinoma and 35 paraffin embedded tissues of the patients with fibro adenoma as control<br />group were collected. The deparaffinization of all the samples were carried out and the DNA was extracted. Initially,<br />the PCR test was carried out to detect beta –globulin DNA as an internal control. For those samples positive for beta<br />–globulin DNA, Polymerase Chain reaction (PCR) was used to detect HCMV for the tests and control samples. Results:<br />Among 37 ductal breast carcinoma, 20 (54.04%) cases were proved positive for HCMV DNA by PCR. While among<br />the 35 control group (fibroadenoma), 10 (28.57%) cases were positive for HCMV DNA (P >0.028). The prevalences of<br />HCMV DNA among the age groups 30-39, 40-49 and >50 years were 7 (72.22%), 9 (69.23%), 4 (57.14%), respectively<br />(P=0.066). A high frequency of HCMV DNA was detected in tumor grade III, 13/18 (58.33%) compared with tumor<br />grade II, 7/19 (36.84%) (p=0.044). A high frequency of 16/24 (66.66%) of HCMV DNA was found in invasive ductal<br />breast cancer compared with 4/13 (30.76%) HCMV DNA in situ (P<0.028). Conclusion: A high prevalence of 54.05%<br />HCMV was found among the patients with ductal carcinoma. The percentages of the high prevalence of HCMV among<br />age group (40-49) years, tumors grades, and invasive stage were (69.23%), (58.33%), (66.66%), respectively. Further<br />study of HCMV in the latency phase in patients with ductal carcinoma would be necessary to extend our knowledge.